N
Nicolle Kraenkel
Researcher at Charité
Publications - 25
Citations - 1227
Nicolle Kraenkel is an academic researcher from Charité. The author has contributed to research in topics: Internal medicine & Progenitor cell. The author has an hindex of 11, co-authored 20 publications receiving 885 citations. Previous affiliations of Nicolle Kraenkel include University of Zurich & University of Bristol.
Papers
More filters
Journal ArticleDOI
Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology:
Marco Ambrosetti,Ana Abreu,Ugo Corrà,Constantinos H. Davos,Dominique Hansen,Ines Frederix,Marie Christine Iliou,Roberto F E Pedretti,Jean-Paul Schmid,Carlo Vigorito,Heinz Völler,Mathias Wilhelm,Massimo F Piepoli,Birna Bjarnason-Wehrens,Thomas Berger,Alain Cohen-Solal,Véronique Cornelissen,Paul Dendale,Wolfram Doehner,Dan Gaita,Andreas B. Gevaert,Hareld M. C. Kemps,Nicolle Kraenkel,Jari A. Laukkanen,Miguel Mendes,Josef Niebauer,Maria Simonenko,Ann-Dorthe Zwisler +27 more
TL;DR: Secondary prevention through comprehensive cardiac rehabilitation has been recognized as the most cost-effective intervention to ensure favourable outcomes across a wide spectrum of cardiovascular ...
Journal ArticleDOI
Diabetes mellitus induces bone marrow microangiopathy
Atsuhiko Oikawa,Mauro Siragusa,Federico Quaini,Giuseppe Mangialardi,Rajesh Katare,Andrea Caporali,Jaap D. van Buul,Floris P. J. van Alphen,Gallia Graiani,Gaia Spinetti,Nicolle Kraenkel,Lucia Prezioso,Costanza Emanueli,Paolo Madeddu +13 more
TL;DR: Novel evidence is provided for the presence of microangiopathy impinging on the integrity of diabetic BM and the framework for mechanistic solutions of BM dysfunction in diabetes is offered.
Journal ArticleDOI
Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies
TL;DR: New approaches of regenerative medicine using vascular progenitor cells for the treatment of ischaemic disease have been shown to be safe and are now being tested for efficacy in pre-clinical and clinical trials.
Journal ArticleDOI
Neurotrophin p75 Receptor (p75NTR) Promotes Endothelial Cell Apoptosis and Inhibits Angiogenesis. Implications for Diabetes-Induced Impaired Neovascularization in Ischemic Limb Muscles
Andrea Caporali,Elisabetta Pani,Anton J.G. Horrevoets,Nicolle Kraenkel,Atsuhiko Oikawa,Graciela B. Sala-Newby,Marco Meloni,Brunella Cristofaro,Gallia Graiani,Aurelie S. Leroyer,Chantal M. Boulanger,Gaia Spinetti,Sung Ok Yoon,Paolo Madeddu,Costanza Emanueli +14 more
TL;DR: It is shown that gene transfer-induced p75NTR expression impairs the survival, proliferation, migration, and adhesion capacities of cultured ECs and endothelial progenitor cells (EPCs) and inhibits angiogenesis in vitro and new avenues for the therapeutic use of p 75NTR inhibition to combat diabetes-induced microvascular liabilities are opened.
Journal ArticleDOI
Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety.
Stephan Winnik,Christine Lohmann,Giovanni Siciliani,Tobias von Lukowicz,Kira Kuschnerus,Nicolle Kraenkel,Chad Brokopp,Frank Enseleit,Stephan Michels,Frank Ruschitzka,Thomas F. Lüscher,Christian M. Matter +11 more
TL;DR: Systemic V EGF inhibition disrupts endothelial homeostasis and accelerates atherogenesis, suggesting that these events contribute to the clinical cardiovascular adverse events of VEGF-inhibiting therapies.